Cinclus i Media | Vetenskapliga artiklar

Vetenskapliga artiklar

2025

Pharmacokinetics and pharmacodynamics of linaprazan glurate after multiple oral doses up to 14 days in healthy subjects

2026-01-01

The acid control properties of LG were presented as the holding time ratio (HTR) and mean pH during Day 1 and 14 of LG administered once daily (QD) or twice daily (BID) at 3 dose levels during 14 days

Optimised biopharmaceutical and pharmacokinetic properties of a Linaprazan glurate tablet formulation to be used in phase 3

2025-10-01

The PK of two tablet formulations were compared in a single-dose, 100 mg LG, 3-way crossover study. Additionally, the food effect on the PK of the LG HCl tablet was assessed.

Clinical Trial - Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis

2025-05-01

Aim: To evaluate the 4-week healing rate and safety of four linaprazan glurate dosing regimens in patients with erosive oesophagitis.

Optimised biopharmaceutical and pharmacokinetic properties of a linaprazan glurate tablet formulation to be used in phase 3

2025-05-01

Healthy subjects were dosed with 54 and 72 evaluable for PK in each of the studies. The exposure of LG was approximately 10-fold lower than for L following single and repeated dosing.

Pharmacokinetics and pharmacodynamics of linaprazan glurate after Multiple oral doses up to 14 days in healthy subjects

2024-10-01

73 healthy subjects randomized into six dosing groups and received LG, a total of 67 subjects completed the study and had at least one evaluable pH measurement.

Linaprazan glurate is highly effective in treating moderate to severe Erosive esophagitis- a double-blind, randomized, dose finding study

2023-10-01

Aims & Methods: This is a randomized, double-blind, active comparator-controlled, 5-arm parallel group, dose-finding study of LG, with lansoprazole (LAN) as the active comparator.

Linaprazan glurate is well tolerated in the treatment of patients with Erosive esophagitis- a double-blind, randomized, dose finding study

2023-10-01

This is a randomized, double-blind, active comparator-controlled, 5-arm parallel group, dose-finding study of LG, with LAN as the active comparator, on the 4-week healing of erosive esophagitis.

Linaprazan glurate is highly effective in treating moderate to severe erosive esophagitis- a double-blind, randomized, dose finding study

2023-05-01

A high healing rate was seen after 4 weeks of LG treatment in the overall C/D cohort, with the highest healing rate seen for 75 mg.

Pharmacokinetics and pharmacodynamics of linaprazan glurate aftermultiple oral doses up to 14 days in healthy subjects

73 healthy subjects were randomized into six dosing groups and received IMP; 67 subjects completed thestudy and had at least one evaluable pH measurement.